Atlas FDA

Alinity m CMV

FDA premarket approval P210022/S004 · decided 2023-03-31

Approval details

PMA number
P210022
Supplement
S004
Supplement type
30-Day Notice
Supplement reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Trade name
Alinity m CMV
Generic name
Cytomegalovirus (cmv) dna quantitative assay
Applicant
Abbott Molecular, Inc.
Date received
2023-03-08
Decision date
2023-03-31
Days to decision
23 days
Decision code
OK30
Product code
PAB
Advisory committee
Microbiology
Expedited review
No
Location
Des Plaines, IL
Statement
Change the temperature and time manufacturing process parameters for kit components.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Alinity m HCV (K252102)Abbott Molecular, Inc.2025-09-25
Alinity m EBV (09N43-095) (K243489)Abbott Molecular, Inc.2025-07-28
Alinity m CMV (K243485)Abbott Molecular, Inc.2025-07-01
Alinity m BKV (K241921)Abbott Molecular, Inc.2025-03-24
Alinity m Resp-4-Plex (K241573)Abbott Molecular, Inc.2025-02-14
Alinity m HSV 1 & 2 / VZV (K233349)Abbott Molecular, Inc.2024-05-03
Alinity m STI Assay (K222379)Abbott Molecular, Inc.2023-03-03
Alinity m EBV AMP Kit (List No. 09N43-095), Alinity m EBV CTRL Kit (List No. 09N43-085), Alinity m EBV CAL Kit (List No. 09N43-075) (K212778)Abbott Molecular, Inc.2022-07-15